GSL Synthetase Inhibitor Eliglustat Combined With CD30 Target Immunotherapy for the Treatment of of CD30+ Lymphoma
Clinical trial NCT07138547 · RECRUITING
Trial details
- NCT number
- NCT07138547
- Sponsor
- Chinese PLA General Hospital
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-12-26
- Primary completion
- 2028-08-31
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.